Spots Global Cancer Trial Database for pdac
Every month we try and update this database with for pdac cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | NCT05634720 | Pancreatic Duct... | HA Chemotherapy | 18 Years - | Duke University | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Identify microRNAs in Cachexia in Pancreatic Carcinoma | NCT05275075 | Resectable Panc... | Pancreatic canc... | 18 Years - | University of Oklahoma | |
| Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. | NCT05340569 | Pancreas Cancer... Pancreas Adenoc... Peritoneal Meta... Peritoneal Carc... | Whole-body diff... | 18 Years - | Laval University | |
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma | NCT02978547 | Resectable Panc... | Metformin Hydro... | 18 Years - | British Columbia Cancer Agency | |
| Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma. | NCT05340569 | Pancreas Cancer... Pancreas Adenoc... Peritoneal Meta... Peritoneal Carc... | Whole-body diff... | 18 Years - | Laval University | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients | NCT05947825 | PDAC - Pancreat... | Combination of ... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | NCT02912949 | Solid Tumours H... NSCLC Harboring... Pancreatic Canc... NRG1 Fusion | zenocutuzumab (... | 18 Years - | Merus N.V. | |
| Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | NCT03404960 | Pancreatic Aden... | Niraparib + Niv... Niraparib + Ipi... | 18 Years - | University of Pennsylvania | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC | NCT06059001 | Metastatic Panc... | OMO-103 Nab-Paclitaxel Gemcitabine | 18 Years - | Peptomyc S.L. | |
| ExoLuminate Study for Early Detection of Pancreatic Cancer | NCT05625529 | Pancreas Cancer Exosomes Extracellular V... Pancreatic Neop... | 18 Years - | Biological Dynamics | ||
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | NCT02912949 | Solid Tumours H... NSCLC Harboring... Pancreatic Canc... NRG1 Fusion | zenocutuzumab (... | 18 Years - | Merus N.V. | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | NCT05642962 | Metastatic Panc... Metastatic Panc... Metastatic Panc... Metastatic Panc... Pancreatic Carc... Pancreatic Carc... Pancreatic Carc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... PDAC PDAC - Pancreat... | Pertzye | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC | NCT06059001 | Metastatic Panc... | OMO-103 Nab-Paclitaxel Gemcitabine | 18 Years - | Peptomyc S.L. | |
| Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | NCT06105021 | Pancreatic Duct... Non-Small Cell ... Colorectal Canc... Solid Tumor KRAS G12V | AFNT-211 | 18 Years - | Affini-T Therapeutics, Inc. | |
| Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | NCT02550327 | Pancreatic Aden... | Nab-paclitaxel Gemcitabine Cisplatin Anakinra | 18 Years - | Baylor Research Institute | |
| Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma | NCT05262855 | PDAC - Pancreat... FAP | [68Ga]FAPI-46 | 18 Years - | SOFIE | |
| ExoLuminate Study for Early Detection of Pancreatic Cancer | NCT05625529 | Pancreas Cancer Exosomes Extracellular V... Pancreatic Neop... | 18 Years - | Biological Dynamics | ||
| Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC) | NCT05727319 | Pancreatic Duct... | 18 Years - | NHS Greater Glasgow and Clyde | ||
| Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma | NCT05262855 | PDAC - Pancreat... FAP | [68Ga]FAPI-46 | 18 Years - | SOFIE | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC | NCT06059001 | Metastatic Panc... | OMO-103 Nab-Paclitaxel Gemcitabine | 18 Years - | Peptomyc S.L. | |
| Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients | NCT04888312 | Metastatic Panc... | CD40 agonist mi... | 18 Years - | Alligator Bioscience AB | |
| Novel MRI Techniques for Pancreatic Cancer | NCT04306861 | Pancreatic Duct... | MRI | 18 Years - | Beth Israel Deaconess Medical Center | |
| Novel MRI Techniques for Pancreatic Cancer | NCT04306861 | Pancreatic Duct... | MRI | 18 Years - | Beth Israel Deaconess Medical Center | |
| 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma | NCT05275985 | PDAC | 68Ga-FAPI Posit... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| First-in-human Navigation Endoscopic Ultrasound (EUS) System Clinical Study | NCT05515705 | Pancreatic Dise... | EUS navigation ... | 18 Years - | IHU Strasbourg | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | NCT04612530 | Pancreatic Canc... Metastatic Panc... | Irreversible El... Nivolumab Toll-Like Recep... | 18 Years - 100 Years | Amsterdam UMC, location VUmc | |
| Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers | NCT04449406 | Pancreatic Duct... | 18 Years - | Queen Mary University of London | ||
| Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX | NCT06349278 | Pancreas Adenoc... Pancreas Metast... Pancreas Cancer | Pancreatic rese... | 18 Years - | Laval University | |
| Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers | NCT04449406 | Pancreatic Duct... | 18 Years - | Queen Mary University of London | ||
| ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | NCT05355298 | Pancreatic Canc... PDAC Pancreatic Duct... | AMP945 ascendin... AMP945 RP2D | 18 Years - | Amplia Therapeutics Limited | |
| Pancreatic Cancer Recurrence in the Netherlands | NCT04605237 | Pancreatic Duct... Pancreatic Canc... Pancreas Cancer PDAC | - | UMC Utrecht | ||
| Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients | NCT05947825 | PDAC - Pancreat... | Combination of ... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | NCT05314998 | Pancreatic Duct... | Oxaliplatin Irinotecan Folinic acid 5-fluorouracil Gemcitabine Capecitabine | 18 Years - 79 Years | Heidelberg University | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| A Study of ASP3082 in Adults With Previously Treated Solid Tumors | NCT05382559 | Solid Tumor | ASP3082 Cetuximab Chemotherapy 1 Chemotherapy 2 | 18 Years - | Astellas Pharma Inc | |
| A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | NCT03637491 | Pancreatic Canc... | Avelumab Binimetinib Talazoparib | 18 Years - | Pfizer | |
| Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer | NCT02361320 | Pancreatic Canc... | Computed Tomogr... Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Identify microRNAs in Cachexia in Pancreatic Carcinoma | NCT05275075 | Resectable Panc... | Pancreatic canc... | 18 Years - | University of Oklahoma | |
| A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX | NCT03450018 | Metastatic Panc... | SLC-0111 Gemcitabine Inj... | 18 Years - | British Columbia Cancer Agency |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
